Department of Biomedical Sciences and NovoNordisk Foundation Center for Basic Metabolic Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Dig Dis Sci. 2022 Jul;67(7):2716-2720. doi: 10.1007/s10620-022-07519-3. Epub 2022 May 30.
In 1993, my laboratory published an article in Digestive Diseases and Sciences that clearly demonstrated the pronounced effects of the newly discovered intestinal hormone, glucagon-like peptide-1 (GLP-1), on a number of gastrointestinal functions, including gastric emptying rate, gastric acid secretion, and pancreatic enzyme secretion. The gut hormone is released in response to nutrient intake, and in further experiments, its release from the ileum paralleled inhibition of both gastric and pancreatic secretions. Based on these studies, it was concluded that GLP-1 is an important regulator of the so-called ileal brake, a term given for the observation that ileal perfusion of lipids delayed gastric emptying, reduced food intake, and induced satiety Welch et al. (1985), in addition to its functions as an incretin hormone. GLP-1 was subsequently identified as a physiological inhibitor of appetite and food intake, and based on these actions, the GLP-1 receptor agonists are today considered among the most powerful and effective antiobesity and antidiabetic agents available, with the added benefits of reducing the risk of the cardiovascular and renal complications associated with these conditions.
1993 年，我的实验室在《消化疾病与科学》杂志上发表了一篇文章，清楚地表明了新发现的肠激素胰高血糖素样肽-1（GLP-1）对许多胃肠道功能的显著影响，包括胃排空率、胃酸分泌和胰腺酶分泌。这种肠道激素是对营养摄入的反应而释放的，在进一步的实验中，其从回肠的释放与胃和胰腺分泌的抑制平行。基于这些研究，我们得出结论，GLP-1 是所谓的回肠制动的重要调节剂，这一术语是指回肠灌注脂质可延迟胃排空、减少食物摄入并引起饱腹感。除了作为肠促胰岛素的作用外，Welch 等人（1985 年）。GLP-1 随后被确定为食欲和食物摄入的生理性抑制剂，基于这些作用，GLP-1 受体激动剂如今被认为是最有效和最有效的抗肥胖和抗糖尿病药物之一，此外还能降低与这些疾病相关的心血管和肾脏并发症的风险。
